Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.

What's in Store for Amgen (AMGN) This Earnings Season?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

Sanghamitra Saha headshot

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $345.64, marking a -1.05% move from the previous day.

Moderna (MRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Sanghamitra Saha headshot

Time for Pharma and Healthcare ETFs?

The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed at $323.48 in the latest trading session, marking a +0.74% move from the prior day.

Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success

Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna (MRNA) closed at $235.15 in the latest trading session, marking a -1.75% move from the prior day.

Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine

Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.

J&J (JNJ) COVID-19 Jab Linked to New Rare Neurological Disorder

FDA warns of increased risk of Guillain-Barre syndrome, a rare neurological disorder with J&J's (JNJ) COVID-19 vaccine.

Company News for Jul 13, 2021

Companies In The News Are: MRNA, DIS, AVGO, JWN

Alexion (ALXN) Hits Fresh High: Is There Still Room to Run?

Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Madeleine Johnson headshot

Bear of the Day: Inovio Pharmaceuticals (INO)

Is it too late to buy this coronavirus vaccine stock?

BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster

BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.

Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine

Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.

The Zacks Analyst Blog Highlights: Shopify, Lowe's, CVS Health, Moderna and The Bank of New York Mellon

The Zacks Analyst Blog Highlights: Shopify, Lowe's, CVS Health, Moderna and The Bank of New York Mellon

Kinjel Shah headshot

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Mark Vickery headshot

Top Research Reports for Shopify, Lowe's & CVS Health

Today's Research Daily features new research reports on 16 major stocks, including Shopify (SHOP), Lowe's Companies (LOW), and CVS Health (CVS).

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?